These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Yacoubian TA; Slone SR; Harrington AJ; Hamamichi S; Schieltz JM; Caldwell KA; Caldwell GA; Standaert DG Cell Death Dis; 2010; 1(1):e2. PubMed ID: 21152247 [TBL] [Abstract][Full Text] [Related]
4. 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax. Slone SR; Lesort M; Yacoubian TA PLoS One; 2011; 6(7):e21720. PubMed ID: 21799745 [TBL] [Abstract][Full Text] [Related]
5. 14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity. Pattanayak R; Ekkatine R; Petit CM; Yacoubian TA Hum Mol Genet; 2024 Nov; 33(23):2071-2083. PubMed ID: 39324210 [TBL] [Abstract][Full Text] [Related]
6. 14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity. Pattanayak R; Petit CM; Yacoubian TA bioRxiv; 2023 May; ():. PubMed ID: 37398189 [TBL] [Abstract][Full Text] [Related]
7. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Braithwaite SP; Stock JB; Mouradian MM Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677 [TBL] [Abstract][Full Text] [Related]
8. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease. Ding H; Underwood R; Lavalley N; Yacoubian TA Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634 [TBL] [Abstract][Full Text] [Related]
10. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease. Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417 [TBL] [Abstract][Full Text] [Related]
12. LRRK2 activation in idiopathic Parkinson's disease. Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977 [TBL] [Abstract][Full Text] [Related]
13. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease. Wu W; Sung CC; Yu P; Li J; Chung KKK PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model. Zahra W; Rai SN; Birla H; Singh SS; Rathore AS; Dilnashin H; Singh R; Keswani C; Singh RK; Singh SP CNS Neurol Disord Drug Targets; 2020; 19(7):527-540. PubMed ID: 32787765 [TBL] [Abstract][Full Text] [Related]
15. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059 [TBL] [Abstract][Full Text] [Related]
16. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
17. UNC-51-like kinase 1 blocks S6k1 phosphorylation contributes to neurodegeneration in Parkinson's disease model in vitro. Li Y; Zhang J; Yang C Biochem Biophys Res Commun; 2015 Apr; 459(2):196-200. PubMed ID: 25680463 [TBL] [Abstract][Full Text] [Related]
19. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. Schapansky J; Nardozzi JD; LaVoie MJ Neuroscience; 2015 Aug; 302():74-88. PubMed ID: 25284317 [TBL] [Abstract][Full Text] [Related]
20. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]